诺华-话题@MedSci

#诺华#

235篇内容 | 4971人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1282793, encodeId=09a41282e93ce, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华与英国NHS联合，以快速推进胆固醇PCSK9的基因干扰药物inclisiran, objectType=article, longId=186391, objectId=6e90186391ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e90186391ad, replyNumber=0, likeNumber=64, createdTime=2020-01-18, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e90186391ad, moduleTitle=诺华与英国NHS联合，以快速推进胆固醇PCSK9的基因干扰药物inclisiran, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e90186391ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282792, encodeId=80d81282e92c6, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, objectType=article, longId=186385, objectId=ced718638553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced718638553, replyNumber=0, likeNumber=70, createdTime=2020-01-18, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced718638553, moduleTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced718638553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282791, encodeId=884e1282e9190, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗, objectType=article, longId=186027, objectId=868418602e8e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=868418602e8e, replyNumber=0, likeNumber=64, createdTime=2020-01-11, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=868418602e8e, moduleTitle=NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=868418602e8e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282790, encodeId=a95a1282e9090, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华97亿收购的PCSK9的siRNA药物inclisiran，预计将于2020年批准上市, objectType=article, longId=185939, objectId=005818593917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=005818593917, replyNumber=0, likeNumber=75, createdTime=2020-01-10, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=005818593917, moduleTitle=诺华97亿收购的PCSK9的siRNA药物inclisiran，预计将于2020年批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=005818593917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282789, encodeId=43191282e89f0, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华将通过抽签免费提供世界昂贵药物, objectType=article, longId=185204, objectId=8561185204ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8561185204ff, replyNumber=0, likeNumber=56, createdTime=2019-12-26, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8561185204ff, moduleTitle=诺华将通过抽签免费提供世界昂贵药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8561185204ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282788, encodeId=12e41282e8858, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, objectType=article, longId=184902, objectId=8f0518490243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f0518490243, replyNumber=0, likeNumber=119, createdTime=2019-12-19, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f0518490243, moduleTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f0518490243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282787, encodeId=cb6c1282e87cf, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功, objectType=article, longId=184839, objectId=a8c018483912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c018483912, replyNumber=0, likeNumber=68, createdTime=2019-12-18, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c018483912, moduleTitle=诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8c018483912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282786, encodeId=1b151282e8661, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的双重组合哮喘药物QMF149的3期研究成功, objectType=article, longId=184398, objectId=aaac184398d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaac184398d6, replyNumber=0, likeNumber=98, createdTime=2019-12-09, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaac184398d6, moduleTitle=诺华的双重组合哮喘药物QMF149的3期研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaac184398d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282785, encodeId=2e381282e85c6, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华肿瘤两大事业部负责人确定, objectType=article, longId=184322, objectId=8dfb1843225d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dfb1843225d, replyNumber=0, likeNumber=64, createdTime=2019-12-08, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dfb1843225d, moduleTitle=诺华肿瘤两大事业部负责人确定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dfb1843225d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282784, encodeId=1a9e1282e8432, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=FDA批准了诺华多发性硬化症药物Gilenya的仿制药, objectType=article, longId=184300, objectId=0ae61843008b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ae61843008b, replyNumber=0, likeNumber=57, createdTime=2019-12-08, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ae61843008b, moduleTitle=FDA批准了诺华多发性硬化症药物Gilenya的仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ae61843008b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282783, encodeId=27d21282e8311, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华宣布以97亿美元收购The Medicines Company，同时获得PCSK9的siRNA抑制剂, objectType=article, longId=184019, objectId=daf618401931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daf618401931, replyNumber=0, likeNumber=34, createdTime=2019-12-04, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daf618401931, moduleTitle=诺华宣布以97亿美元收购The Medicines Company，同时获得PCSK9的siRNA抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daf618401931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282782, encodeId=dddb1282e829f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华心衰创新药经谈判纳入2019医保目录，报销比例**达90%, objectType=article, longId=183786, objectId=520e183e8673, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=520e183e8673, replyNumber=0, likeNumber=111, createdTime=2019-11-30, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=520e183e8673, moduleTitle=诺华心衰创新药经谈判纳入2019医保目录，报销比例**达90%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=520e183e8673)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282781, encodeId=fc7b1282e814a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=近100亿美元收购创新降脂疗法诺华揭示心血管疾病布局, objectType=article, longId=183660, objectId=106018366048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=106018366048, replyNumber=0, likeNumber=76, createdTime=2019-11-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=106018366048, moduleTitle=近100亿美元收购创新降脂疗法诺华揭示心血管疾病布局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=106018366048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282780, encodeId=91d11282e801e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？, objectType=article, longId=183458, objectId=aa7d1834581c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7d1834581c, replyNumber=0, likeNumber=54, createdTime=2019-11-24, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7d1834581c, moduleTitle=美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7d1834581c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282779, encodeId=e7c71282e79e2, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的Adakveo获得FDA批准治疗镰状细胞性疼痛, objectType=article, longId=183194, objectId=5578183194d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5578183194d4, replyNumber=0, likeNumber=62, createdTime=2019-11-20, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5578183194d4, moduleTitle=诺华的Adakveo获得FDA批准治疗镰状细胞性疼痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5578183194d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282778, encodeId=48951282e7815, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华与中关村创业大街联合举办数字创新路演活动：聚焦数字医疗，加速中国医药领域转型和发展, objectType=article, longId=182955, objectId=fabc1829552b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fabc1829552b, replyNumber=0, likeNumber=62, createdTime=2019-11-15, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fabc1829552b, moduleTitle=诺华与中关村创业大街联合举办数字创新路演活动：聚焦数字医疗，加速中国医药领域转型和发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fabc1829552b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282777, encodeId=fbbb1282e77bb, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市, objectType=article, longId=182505, objectId=788918250583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=788918250583, replyNumber=0, likeNumber=92, createdTime=2019-11-08, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=788918250583, moduleTitle=诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=788918250583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282776, encodeId=a1ea1282e7658, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=银屑病关节炎头对头实验中，诺华的IL-17单抗Cosentyx与Humira相比未能实现统计学意义的改善, objectType=article, longId=182337, objectId=c39f18233ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c39f18233ed9, replyNumber=0, likeNumber=78, createdTime=2019-11-05, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c39f18233ed9, moduleTitle=银屑病关节炎头对头实验中，诺华的IL-17单抗Cosentyx与Humira相比未能实现统计学意义的改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c39f18233ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282775, encodeId=d42d1282e752c, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的新型IgE单抗Ligelizumab在自发性荨麻疹试验中胜过奥马珠单抗, objectType=article, longId=181142, objectId=9f1e18114253, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1e18114253, replyNumber=0, likeNumber=62, createdTime=2019-10-16, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1e18114253, moduleTitle=诺华的新型IgE单抗Ligelizumab在自发性荨麻疹试验中胜过奥马珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f1e18114253)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282774, encodeId=cae91282e7442, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果, objectType=article, longId=180608, objectId=b0ed180608a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0ed180608a6, replyNumber=0, likeNumber=62, createdTime=2019-10-08, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0ed180608a6, moduleTitle=诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0ed180608a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

诺华

2020-05-29发表于威斯康星

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华与英国NHS联合，以快速推进胆固醇PCSK9的基因干扰药物inclisiran

2020-01-18

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx

2020-01-18

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗

2020-01-11

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华97亿收购的PCSK9的siRNA药物inclisiran，预计将于2020年批准上市

2020-01-10

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华将通过抽签免费提供世界昂贵药物

2019-12-26

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant

2019-12-19

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功

2019-12-18

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的双重组合哮喘药物QMF149的3期研究成功

2019-12-09

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华肿瘤两大事业部负责人确定

2019-12-08

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

FDA批准了诺华多发性硬化症药物Gilenya的仿制药

2019-12-08

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华宣布以97亿美元收购The Medicines Company，同时获得PCSK9的siRNA抑制剂

2019-12-04

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华心衰创新药经谈判纳入2019医保目录，报销比例**达90%

2019-11-30

仁者大医 (审核中...)

前往app查看评论内容

#诺华#

近100亿美元收购创新降脂疗法诺华揭示心血管疾病布局

2019-11-28

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？

2019-11-24

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的Adakveo获得FDA批准治疗镰状细胞性疼痛

2019-11-20

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华与中关村创业大街联合举办数字创新路演活动：聚焦数字医疗，加速中国医药领域转型和发展

2019-11-15

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市

2019-11-08

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

银屑病关节炎头对头实验中，诺华的IL-17单抗Cosentyx与Humira相比未能实现统计学意义的改善

2019-11-05

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的新型IgE单抗Ligelizumab在自发性荨麻疹试验中胜过奥马珠单抗

2019-10-16

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果

2019-10-08

科室
- - 订阅+
  - 更多科室
工具
服务